WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

A Review on Problem of Antibiotic Resistance and Rational Use of Antibiotic

[1]Pankaj Prabhakr Pagar, [2]Prof. Vandana. V. Shirsath

[1]Kalvan, Distt. Nashik
[2]Shree Mahavir Institute of Pharmacy, Nashik India

ABSTRACT-

Updated national death and infection estimates are included in the CDC's Antibiotic Resistance Threats in the United States, 2019 (2019 AR Threats Report), which highlights the ongoing threat of antibiotic resistance in the country. Although the threat posed by antibiotic resistance in the United States was larger than first thought, new CDC data show that mortality have been declining since the 2013 study. This indicates that American attempts to avoid illnesses, reducing bacterial and fungal spread and enhancing antibiotic use in people, animals, and the environment are effective, particularly in hospitals. When possible, vaccination has also proven to be an effective method of avoiding illnesses in the community, including those that may be resistant.

However, there are still too many people in the United States who are affected by antibiotic resistance. Each year, more than 2.8 million antibiotic-resistant illnesses occur in the US, leading to more than 35,000 fatalities. Additionally, in 2017 at least 12,800 Americans died and nearly 223,900 needed hospital care for C. difficile.

INTRODUCTION-

People have fought a never-ending war against a variety of microbes that spread sickness and infection throughout history. antibiotic resistance, or the capacity of bacteria and other microbes to withstand an antibiotic and inhibit it at the infection site

Resistance.

A global issue is antibiotic resistance. Antibiotic resistance strains are easily transported across national borders and between continents. Numerous forms of resistance spread quickly. Antibiotic-resistant bacteria have been referred to by global health authorities as "nightmare bugs" that "represent a catastrophic threat" to people everywhere in the world.

At least 2 million people in the United States suffer serious infections every year from germs that are resistant to one or more of the antibiotics used to treat such infections. These illnesses that are resistant to antibiotics cause at least 23,000 deaths annually. Many more people pass away from illnesses that were made worse by an infection that was resistant to antibiotics.

In addition, C. difficile infections affect almost 250,000 patients annually who need hospital care. The usage of antibiotics was a significant factor contributing to the sickness in the majority of these illnesses. Each year, at least 14,000 people pass away in the United

PROBLEM OF ANTIBIOTIC RESISTANCE-

In both cataract and refractive operations, the new generation of fluoroquinolones has found widespread application in the prevention of endophthalmitis and postoperative infections. When compared to the spectrum of prior genera- tions of fluoroquinolones, the fourth generation's structural changes have improved the fourth generation's spectrum of activity against numerous gram-positive bacteria.

Limited Knowledge Gaps Regarding Antibiotic Resistance Capacity at the national, state, and federal levels to identify and address immediate and emerging antibiotic resistance threats

We do not have a clear picture of the domestic incidence, prevalence, mortality, and cost of resistance, not even for major pathogens of concern as carbapenem-resistant Enterobacteriaceae (CRE) and Neisseria gonorrhoeae.

There is currently no systematic international surveillance of threats from antibiotic resistance.



STOPPING SPREAD OF ANTIBIOTIC RESISTANCE-

These inpatient and outpatient programmes have a lot of potential to lower the threat of antibiotic resistance, enhance patient outcomes, and save money on healthcare. Threats can be identified by advanced technologies much more quickly than by current methods.

The United States does not make as much use of advanced molecular detection (AMD) technologies as it should. These technologies can discover AR risks far faster than is currently the case.

These drugs shouldn't be prescribed any less frequently than four times each day. Additionally, antibiotics should only be used for the time allotted by the doctor in order to effectively kill microorganisms or give enough prophylaxis against them. The use of fourth-generation fluoroquinolones after regular cataract surgery is one example.

For around 7 days, these drugs should be taken four times daily, then abruptly stopped. Because low level, prolonged exposure is a formula for bacterial resistance development, there should be no tapering or long-term usage of these medicines.

Four Core Actions to Prevent Preventing Infections include the administration of the best antibiotic at the best dosage for the best amount of time.

CONCLUSION-

A current field of study is improving existing drug classes to combat positive-function resistance.

New medications are not impacted by current resistance mechanisms may be created by concentrating on the development and discovery of novel chemical compounds to block one or even several enzyme targets,

REFERENCE-

1. Premier healthcare database white paper. data that informs and performs. 2018. (Accessed August 14, 2019, at https://leam.premierinc.com/white-papers/premier-healthcare-database—whitepaper.)

2. DeShazo JPI Hoffman MA. A comparison Of a multistate inpatient HER database to the HCUP Nationwide Inpatient Sample. BMC Health Serv Res 2015;15:384.

3. Tabak YP, Zilberberg MD, Johannes RS, Sun X, McDonald LC. Attributable burden of hospital-onset Clostridium difficile infection: a propensity score matching study. Infect Control Hosp Epidemiol

4. Ridgway JP, Sun X, Tabak YP, Johannes RS, Robicsek A. Performance characteristics and associated outcomes for an automated surveillance tool for bloodstream infection. Alnfect Control 2016;44:567-71.

5. McCann E, Srinivasan A, DeRyke CA et al. Carbapenem-Nonsusceptible Gram-Negative Pathogens in ICU and Non-ICU Settings in US Hospitals in 2017: A Multicenter Study. Open Forum Infect Dis 2018;5:ofy241. doi: 10.1093/0fid/ofy241

6. Brossette SE, Hacek DM, Gavin PJ, et al. A laboratory-based, hospital-wide, electronic marker for nosocomial infection: the future of infection control surveillance? Am J Clin Pathol

7. American Hospital Association. AHA annual survey database Chicago, IL: American Hospital Association; 2017. http://www.ahadata.com/

8. Robust Inference With Mufti-way Clustering. National Bureau of Economic Research. (Accessed August

9. Thompson S. Simple formulas for standard errors that cluster by both firm and time. Journal of financial economics

10. Nelson RE, Slayton RB, Stevens VW, et al. Attributable Mortality of Healthcare-Associated Infections Due to Multidrug-Resistant Gram-Negative Bacteria and Methicillin-Resistant Staphylococcus Aureus.Infection control and hospital epidemiology

11. Wolkewitz, M., J. Beyersmann, P. Gastmeier, and M. Schumacher. 2009. Efficient risk set sampling when a time-dependent exposure is present: matching for time to exposure versus exposure density sampling. Methods Inf. Med. 48:438—443.

12. Blizzard L, Hosmer DW. Parameter estimation and goodness-of-fit in log binomial regression. Biom

13. Cummings P. The relative merits of risk ratios and odds ratios. Arch Pediatr Adolesc Med

14. Greenland S. Model-based estimation of relative risks and other epidemiologic measures in studies of common outcomes and in case-control studies. Am J Epidemiol 2004160:301-5.

15. Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol RE et al. Attributable cost and Length of Stay Associated with Nosocomial Gram-Negative Bacterial Cultures. Antimicrob Agents Chemother. 2018 Oct 24;62(11)

16. Wagner T, Chow A, su P, Barnett PG. HERC's Average cost Datasets for VA Inpatient Care, FYI 998-FY2016. Guidebook. VA Palo Alto Health Economics Resource Center; May 2017.

17. Matsumura JS, Stroupe KT, Lederle FAT et al. Costs of repair of abdominal aortic aneurysm with different devices in a multicenter randomized trial. J Vasc Surg. 2015;61

18. Wagner TH. Upadhyay A, Cowgill E, et al. Risk Adjustment Tools for Learning Health Systems: A Comparison of DxCG and CMS-HCC V21. Health Serv Res. 2016;51

19. Mihaylova B, Briggs A, O'Hagan A, Thompson SG. Review of statistical methods for analyzing healthcare resources and costs. Health Econ. 011;20(8):897—916. doi:10.10 Factors impacting on the problem of antibiotic resistance